JPWO2019199864A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019199864A5 JPWO2019199864A5 JP2020555501A JP2020555501A JPWO2019199864A5 JP WO2019199864 A5 JPWO2019199864 A5 JP WO2019199864A5 JP 2020555501 A JP2020555501 A JP 2020555501A JP 2020555501 A JP2020555501 A JP 2020555501A JP WO2019199864 A5 JPWO2019199864 A5 JP WO2019199864A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- pharmaceutically acceptable
- acceptable salt
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 156
- 150000001875 compounds Chemical class 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000021908 Myocardial disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 5
- 208000027868 Paget disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 241001303601 Rosacea Species 0.000 claims description 5
- 208000010641 Tooth disease Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 230000037444 atrophy Effects 0.000 claims description 5
- 230000004900 autophagic degradation Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 230000000938 luteal effect Effects 0.000 claims description 5
- 208000027202 mammary Paget disease Diseases 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 230000003387 muscular Effects 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 201000004700 rosacea Diseases 0.000 claims description 5
- 230000002123 temporal effect Effects 0.000 claims description 5
- -1 -haloalkyl Chemical group 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655741P | 2018-04-10 | 2018-04-10 | |
| US62/655,741 | 2018-04-10 | ||
| PCT/US2019/026634 WO2019199864A1 (en) | 2018-04-10 | 2019-04-09 | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521178A JP2021521178A (ja) | 2021-08-26 |
| JP2021521178A5 JP2021521178A5 (https=) | 2022-04-13 |
| JPWO2019199864A5 true JPWO2019199864A5 (https=) | 2022-04-13 |
| JP7369139B2 JP7369139B2 (ja) | 2023-10-25 |
Family
ID=66248833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555501A Active JP7369139B2 (ja) | 2018-04-10 | 2019-04-09 | Ｐｉ３キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11492348B2 (https=) |
| EP (1) | EP3774783B1 (https=) |
| JP (1) | JP7369139B2 (https=) |
| KR (1) | KR102803762B1 (https=) |
| CN (1) | CN112189012B (https=) |
| AU (1) | AU2019251360B2 (https=) |
| EA (1) | EA202092444A1 (https=) |
| ES (1) | ES3032793T3 (https=) |
| MX (1) | MX2020010576A (https=) |
| SG (1) | SG11202008832TA (https=) |
| WO (1) | WO2019199864A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3032793T3 (en) | 2018-04-10 | 2025-07-24 | Neuropore Therapies Inc | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
| MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| IL325201A (en) | 2019-06-17 | 2026-02-01 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of using them |
| CN113121499B (zh) * | 2021-04-13 | 2022-05-31 | 海南锦瑞制药有限公司 | 奥美拉唑的合成方法及应用 |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| WO2008098058A1 (en) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| AU2009256574A1 (en) * | 2008-06-13 | 2009-12-17 | Novartis Ag | 2,4'-bipyridinyl compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| EP2475375A4 (en) | 2009-09-09 | 2013-02-20 | Avila Therapeutics Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| EP2683243A4 (en) | 2011-03-09 | 2014-12-03 | Celgene Avilomics Res Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| ES2608967T3 (es) | 2011-03-28 | 2017-04-17 | Mei Pharma, Inc. | (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas |
| RU2688665C2 (ru) * | 2014-04-22 | 2019-05-22 | Университет Базель | Новый способ получения производных триазина, пиримидина и пиридина |
| AU2015366357B2 (en) | 2014-12-17 | 2018-07-19 | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof |
| DK3416957T3 (da) | 2016-02-19 | 2020-09-21 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes |
| AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
| CN112533917B (zh) | 2018-04-10 | 2024-06-21 | 神经孔疗法股份有限公司 | 作为vps34的抑制剂的吗啉衍生物 |
| ES3032793T3 (en) * | 2018-04-10 | 2025-07-24 | Neuropore Therapies Inc | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
-
2019
- 2019-04-09 ES ES19719101T patent/ES3032793T3/es active Active
- 2019-04-09 EP EP19719101.8A patent/EP3774783B1/en active Active
- 2019-04-09 AU AU2019251360A patent/AU2019251360B2/en active Active
- 2019-04-09 MX MX2020010576A patent/MX2020010576A/es unknown
- 2019-04-09 KR KR1020207032213A patent/KR102803762B1/ko active Active
- 2019-04-09 SG SG11202008832TA patent/SG11202008832TA/en unknown
- 2019-04-09 JP JP2020555501A patent/JP7369139B2/ja active Active
- 2019-04-09 EA EA202092444A patent/EA202092444A1/ru unknown
- 2019-04-09 WO PCT/US2019/026634 patent/WO2019199864A1/en not_active Ceased
- 2019-04-09 CN CN201980032054.7A patent/CN112189012B/zh active Active
- 2019-04-09 US US17/046,746 patent/US11492348B2/en active Active
-
2022
- 2022-11-07 US US17/982,425 patent/US12049462B2/en active Active
-
2024
- 2024-06-12 US US18/741,572 patent/US20240327396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532112A5 (https=) | ||
| JP2021521178A5 (https=) | ||
| JP2007505933A5 (https=) | ||
| JP2020517707A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2013532652A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2020528062A (ja) | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 | |
| JP2014037426A5 (https=) | ||
| JP2016514719A5 (https=) | ||
| JP2010514797A5 (https=) | ||
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| JP2020529994A5 (https=) | ||
| WO2014129495A1 (ja) | 眼疾患処置薬 | |
| JP2013520473A5 (https=) | ||
| JP2014517836A5 (https=) | ||
| JP2017531678A5 (https=) | ||
| JP2021046404A5 (https=) | ||
| JP7159440B2 (ja) | ジカチオン化合物及びその製造方法と使用 | |
| JP2014514290A5 (https=) | ||
| JP2019520344A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| CA3168807A1 (en) | Methods of treatment for alpha-1 antitrypsin deficiency |